Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone651-259-1600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$217.04 million
Profitability
Miscellaneous
Employees652
OptionableOptionable
Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions
What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
How were Cardiovascular Systems' earnings last quarter?
Cardiovascular Systems Inc (NASDAQ:CSII) announced its quarterly earnings results on Tuesday, October, 30th. The medical device company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.03. The medical device company had revenue of $56.27 million for the quarter, compared to the consensus estimate of $55.96 million. Cardiovascular Systems had a net margin of 0.36% and a return on equity of 0.62%. View Cardiovascular Systems' Earnings History.
When is Cardiovascular Systems' next earnings date?
What guidance has Cardiovascular Systems issued on next quarter's earnings?
Cardiovascular Systems updated its FY 2019 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $243-247 million, compared to the consensus revenue estimate of $244.72 million.Cardiovascular Systems also updated its Q2 2019 guidance to EPS.
What price target have analysts set for CSII?
5 Wall Street analysts have issued 1 year price targets for Cardiovascular Systems' stock. Their forecasts range from $30.00 to $50.00. On average, they anticipate Cardiovascular Systems' stock price to reach $41.6667 in the next twelve months. This suggests a possible upside of 45.3% from the stock's current price. View Analyst Price Targets for Cardiovascular Systems.
What is the consensus analysts' recommendation for Cardiovascular Systems?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardiovascular Systems.
What are Wall Street analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- 1. According to Zacks Investment Research, "Cardiovascular Systems exited first-quarter fiscal 2019 on a mixed note. The company continued to see increased revenues from Atherectomy franchises, growing international sales of OAS and top-line contributions from its emerging product pipeline. We are also upbeat about Cardiovascular Systems’ recent announcement of the first global commercial use of Stealth 360 Peripheral OAS in Hong Kong. Further, the company is progressing well with the international distribution agreement with OrbusNeich to sell its coronary and peripheral OAS outside the United States and Japan. According to management, the company saw the strongest quarterly growth in the first quarter in the last 18 months. Over the past six months, Cardiovascular Systems has outperformed its industry. On the flip side, the company faces cut-throat competition in the niche space. Further, its failure to enter global markets might affect results." (11/12/2018)
- 2. Needham & Company LLC analysts commented, "CSII’s F1Q19 revenue beat while EPS missed consensus and management maintained FY19 revenue guidance. While CSII should continue to benefit from the Japanese launch, an exclusive international distribution agreement (OrbusNeich), new support products, and building rep productivity, we believe there is execution risk in CSII’s long-term transformation (see our analyst meeting note here). Given these points, increasingly difficult comps in FY19, and our belief that CSII shares are fairly valued, we maintain our Hold rating." (10/31/2018)
Has Cardiovascular Systems been receiving favorable news coverage?
News headlines about CSII stock have been trending negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardiovascular Systems earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned media stories about the medical device company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term.
Who are some of Cardiovascular Systems' key competitors?
Some companies that are related to Cardiovascular Systems include Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), Nevro (NVRO), AtriCure (ATRC), K2M Group (KTWO), Luminex (LMNX), Tactile Systems Technology (TCMD) and Cryolife (CRY).
Who are Cardiovascular Systems' key executives?
Cardiovascular Systems' management team includes the folowing people:
- Mr. Scott Raymond Ward M.S., MS, B.Sc., Chairman, Pres & CEO (Age 59)
- Mr. Jeffrey S. Points, Chief Financial Officer (Age 42)
- Ms. Rhonda J. Robb, Chief Operating Officer (Age 51)
- Mr. Alexander Rosenstein, Gen. Counsel & Corp. Sec. (Age 47)
- Ms. Laura J. Gillund, Chief Talent Officer (Age 58)
Who are Cardiovascular Systems' major shareholders?
Cardiovascular Systems' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.15%), Diversified Trust Co (0.03%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Edward M Brown, Jeffrey S Points, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Martha Goldberg Aronson, Sandra Sedo and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.
Which institutional investors are selling Cardiovascular Systems stock?
CSII stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc. and Bank of Montreal Can. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, Jeffrey S Points and Sandra Sedo. View Insider Buying and Selling for Cardiovascular Systems.
Which institutional investors are buying Cardiovascular Systems stock?
CSII stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have bought Cardiovascular Systems stock in the last two years include Martha Goldberg Aronson and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.
How do I buy shares of Cardiovascular Systems?
Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiovascular Systems' stock price today?
One share of CSII stock can currently be purchased for approximately $28.68.
How big of a company is Cardiovascular Systems?
Cardiovascular Systems has a market capitalization of $996.52 million and generates $217.04 million in revenue each year. The medical device company earns $1.71 million in net income (profit) each year or $0.05 on an earnings per share basis. Cardiovascular Systems employs 652 workers across the globe.
What is Cardiovascular Systems' official website?
How can I contact Cardiovascular Systems?
Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]
MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe CSII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSII will underperform the S&P 500 over the long term. You may vote once every thirty days.
